Efficacy and Time to Next Treatment Following Lenalidomide/Rituximab (R-2) or Rituximab/Placebo in Patients with R/R Indolent Nhl (Augment).

AuthID
 P-00R-4A8
18
Author(s)
Gribben, JG
·
Fowler, NH
·
Hong, XN
·
Zhang, HL
·
Offner, F
·
Scheliga, AAS
·
Nowakowski, GS
·
Pinto, A
·
Re, F
·
Fogliatto, LM
·
Scheinberg, P
·
Flinn, I
·
Moreira, C
·
Kalambakas, SA
·
Fustier, P
·
Wu, CQ
·
Leonard, JP
Document Type
Abstract
Year published
2019
Published
in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X
Volume: 37, Issue: 15
Conference
Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: MAY 31-JUN 04, 2019, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol
Indexing
Wos®
Publication Identifiers
Wos: WOS:000487345806276
Source Identifiers
ISSN: 0732-183X
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service